Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT510A vs Ranibizumab in wAMD
NCT05480293Phase 3Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Feb 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SCT510A in exudative macular degeneration (2 arms), sponsored by Sinocelltech Group Limited. Primary endpoint: Mean change from baseline in BCVA at 48 weeks. Status: unknown.
02
Drugs
SCT510A
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT05480293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05480293.